• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Amgen (AMGN) Stock Could Trade At A Discount To Cash Flow

    Simply Wall St·10/31/2026 04:41:04
    语音播报

    Amgen has delivered a powerful share price run in recent years, yet the question for investors today is whether that higher tag is properly underpinned by the cash the business can generate. Fresh clinical results and product updates keep resetting expectations, but the real issue is how much of that future cash flow is already priced into the stock.

    • Over the past 5 years the stock has returned 154.7%, which puts a lot of emphasis on whether the current valuation is fully supported by the cash Amgen can realistically produce over time.
    • Recent positive trial outcomes in oncology and autoimmune conditions may support expectations for stronger and more durable cash flows, but they can also shift the timing and risk profile of those inflows as programs move toward broader commercialization.
    • Prefer to judge Amgen on earnings? See what Amgen's 28.8x P/E says about the price.

    The issue now is whether that recent performance and pipeline progress leave Amgen fairly priced once its cash flows are run through a Discounted Cash Flow (DCF) lens.

    If you want more ideas that rhyme with the Amgen story but fit your own filter on valuation and fundamentals, start a watchlist from the solid balance sheet and fundamentals stocks screener (25 results).

    Does Amgen Look Undervalued on Cash Flow?

    The Discounted Cash Flow (DCF) approach here projects the cash Amgen could return to shareholders over time and then discounts it back to today. On this model, the business is throwing off about $10.8b of free cash flow over the latest twelve months, with analysts and internal estimates pointing to growing cash generation over the coming decade rather than a shrinking profile.

    Those rising free cash flow expectations help explain why the DCF output sits substantially above the current share price of $466.01. Because the recent Phase 3 DeLLphi-305 data for Imdelltra in small cell lung cancer points to another potentially meaningful cash flow stream, the market price still lags what these projections imply for the equity value overall. Find out what Amgen could be worth using our Discounted Cash Flow (DCF) estimate.

    The Amgen Narrative: What Would Justify Today's Price?

    Narratives for Amgen pick up where the DCF puzzle leaves off, spelling out which paths for Amgen's revenue, earnings and margins would need to play out for the stock to be worth much more or much less than today on Simply Wall St's Community page. Instead of stopping at a single output from a ratio or model, Narratives describe the future that number depends on so you can see whether Amgen's actual progress lines up with that script in real time.

    Community views on Amgen are split between a multi platform growth story and a market that already prices in most of that optimism.

    Bull case: 7% undervalued

    "The breadth of Amgen's double digit volume growth now extends across 22 products that each delivered double digit sales growth in the latest quarter..."

    Discover why this Narrative puts Amgen at 7% undervalued.

    Bear case: 29% overvalued

    "MariTide's commercial ramp-up will take years post-launch, while Amgen’s high-margin legacy moats (Prolia and Enbrel) are already eroding at a brutal 30%+ YoY clip right now..."

    Explore why this Narrative puts Amgen at 29% overvalued.

    The Amgen story is not just about what you pay today

    Price and cash flow only tell part of the story for Amgen, because internal checks have also flagged areas of concern that deserve your attention before you commit fresh capital. Take a closer look at 1 warning sign before settling on a valuation.